Sorafenib inhibits the angiogenesis and growth of orthotopic anaplastic thyroid carcinoma xenografts in nude mice

Molecular Cancer Therapeutics

Volumn 6, Issue 6, 2007, Pages 1785-1792

  Kim, Seungwon ^a,c   Yazici, Yasemin D ^a   Calzada, Gabriel ^b   Wang, Zhuo Ying ^a   Younes, Maher N ^a   Jasser, Samar A ^a   El Naggar, Adel K ^a   Myers, Jeffrey N ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; SORAFENIB;

ANAPLASTIC CARCINOMA; ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CANCER SURVIVAL; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFECT; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; THYROID CARCINOMA; TUMOR XENOGRAFT;

ANGIOGENESIS INHIBITORS; ANIMALS; APOPTOSIS; BENZENESULFONATES; CELL DIVISION; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; PYRIDINES; THYROID NEOPLASMS; TRANSPLANTATION, HETEROLOGOUS;

EID: 34250704834     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-06-0595     Document Type: Article

References (20)

1. Sherman SI. Thyroid carcinoma. Lancet 2003;361:501-11.
2. Pasieka JL. Anaplastic thyroid carcinoma. Curr Opin Oncol 2003;15:78-83.
3. Gilliland FD, Hunt WC, Morris DM, Key CR. Prognostic factors for thyroid carcinoma. A population-based study of 15,698 cases from the Surveillance, Epidemiology and End Results (SEERS) program 1973-1991. Cancer 1997;79:564-73.
4. Shimaoka K, Schoenfeld DA, DeWys WD, Creech RH, DeConti R. A randomized trial of doxorubicin versus doxorubicin plus cisplatin in patients with advanced thyroid carcinoma. Cancer 1985;56:2155-60.
5. Ahuja S, Ernst H. Chemotherapy of thyroid carcinoma. J Endocrinol Invest 1987;10:303-10.
6. American Joint Committee on Cancer. In: Fleming ID, et al., editors. American Joint Committee on Cancer manual for staging cancer. 5th ed. Philadelphia: Lippincott-Raven; 1997.
7. Herbst RS. ZD1839: targeting the epidermal growth factor receptor in cancer therapy. Expert Opin Investig Drugs 2002;11:837-49.
8. Wilhelm SM, Carter C, Tang L, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004;64:7099-109.
9. Kim S, Yazici YD, Barber SE, et al. Growth inhibition of orthotopic anaplastic thyroid carcinoma xenografts in nude mice by PTK787/ZK222584 and CPT-11. Head Neck 2006;28:389-99.
10. Schoenberger J, Grimm D, Kossmehl P, Infanger M, Kurth E, Eilles C. Effects of PTK787/ZK222584, a tyrosine kinase inhibitor, on the growth of a poorly differentiated thyroid carcinoma: an animal study. Endocrinology 2004;145:1031-8.
11. Kim S, Schiff BA, Yigitbasi OG, et al. Targeted molecular therapy of anaplastic thyroid carcinoma with AEE788. Mol Cancer Ther 2005;4:632-40.
12. Kim S, Park YW, Schiff BA, et al. An orthotopic model of anaplastic thyroid carcinoma in nude, athymic mouse. Clin Cancer Res 2005;11:1713-21.
13. Clark JW, Eder JP, Ryan D, Lathia C, Lenz HJ. Safety and pharmacokinetics of the dual action Raf kinase and vascular endothelial growth factor receptor inhibitor, BAY 43-9006, in patients with advanced, refractory solid tumors. Clin Cancer Res 2005;11:5472-80.
14. Carlomagno F, Anaganti S, Guida T, et al. BAY 43-9006 inhibition of oncogenic RET mutants. J Natl Cancer Inst 2006;98:326-34.
15. Langley RR, Ramirez KM, Tsan RZ, Van Arsdall M, Nilsson MB, Fidler IJ. Tissue specific microvascular endothelial cell lines from H-2K(b)-tsA58 mice for studies of angiogenesis and metastasis. Cancer Res 2003;63:2971-6.
16. Siu L, Takimoto C, Awada A, et al. A phase I/II trial of BAY 43-9006 and gemcitabine in advanced pancreatic cancer [abstract 3059]. Proc Annu Meet Am Soc Clin Oncol 2004;22:209s.
17. Eisen T, Ahmed T, Gore ME, et al. Phase I trial of BAY 43-9006 (sorafenib) combined with dacarbazine (DTIC) in metastatic melanoma patients [abstract 7508]. Proc Annu Meet Am Soc Clin Oncol 2005;43:712s.
18. Ratain MJ, Eisen T, Stadler WM, et al. Final findings from a phase II, placebo-controlled, randomized discontinued trial (RDT) of sorafenib (BAY 43-9006) in patients with advanced renal cell carcinoma (RCC) [abstract 4544]. Proc Annu Meet Am Soc Clin Oncol 2005;21:388s.
19. O'Dwyer PJ, Rosen M, Gallagher M, Schwartz B, Flaherty KT. Pharmacodynamic study of BAY 43-9006 in patients with metastatic renal cell carcinoma [abstract 3005]. Proc Annu Meet Am Soc Clin Oncol 2005;23:193s.
20. Escudier B, Szczylik C, Eisen T, et al. Randomized phase III trial of the Raf kinase and VEGFR inhibitor sorafenib (BAY 43-9006) in patients with advanced renal cell carcinoma (RCC) [abstract 4510]. Proc Annu Meet Am Soc Clin Oncol 2005;43:380s.